Glycotargeting therapeutics

Abstract

Glycotargeting therapeutics are useful in the treatment of transplant rejection, autoimmune disease, food allergy, and immune response against a therapeutic agent.

1 . A compound for the induction of antigen-specific immune tolerance in a subject, the compound comprising:
 a peptide to which tolerance is desired;
 wherein the peptide to which tolerance is desired, when presented to the subject alone, is capable of inducing an unwanted immune response in the subject; 
   a polymeric linker;
 wherein the polymeric linker is coupled to the peptide to which tolerance is desired via a disulfide bond or a disulfanyl ethyl ester; 
 wherein the disulfide bond or the disulfanyl ethyl ester are each configured to be cleaved upon administration of the compound to the subject and to release the peptide to which tolerance is desired from the polymeric linker; 
 wherein the polymeric linker comprises a 1-cyano-1-methyl-propyl group and methacrylic units comprising an ethylacetamido functionality; and 
   a liver-targeting moiety;
 wherein the liver-targeting moiety comprises a galactosylating moiety; 
 wherein the liver-targeting moiety is coupled to the polymeric linker through the ethylacetamido functionality.